Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Egyptian Price Reform Ruling Soon; What's Next For MNC Drug Makers?

This article was originally published in PharmAsia News

Executive Summary

In less than one month, the Supreme Administrative Court of Egypt will resume proceedings on Decree 373, the new drug pricing scheme proposed by the Ministry of Health to simplify the current system and make prices more predictable. The proposals have encountered balking from both drug makers and consumer advocacy groups, and now healthcare analysts think the reforms may need major reworking

You may also be interested in...



PhamAsia News Top Editors' Picks Of 2010

More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia

PhamAsia News Top Editors' Picks Of 2010

More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia

Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?

Egypt, an emerging pharmaceutical market, is implementing a series of healthcare and drug pricing reforms. The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics in the country

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel